20 June 2016 - The TGA has approved a new indication for Ferring Pharmaceuticals' Glypressin (terlipressin acetate).

Glypressin was approved by the TGA on 10 June 2016 for the treatment of patients with hepatorenal syndrome type 1 to improve short-term survival where liver transplant is being actively considered.

Ferring Pharmaceuticals' Lucassin (terlipressin) was registed by the TGA in 2012 for use in patients with hepatrenal syndrome.

For more details, go to: http://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines